BioCentury | Jun 2, 2020
Tools & Techniques

Spark’s approach to the problem of redosing AAV gene therapies

...Path to Gene Therapy 2.0” ). In Nature Medicine Monday, scientists from Spark Therapeutics Inc., Genethon...
...vaccination efficiency, pretreating with IdeS may be able to boost efficacy. Sandi Wong, Assistant Editor Spark Therapeutics Inc. Roche Genethon Institut...
BioCentury | Jan 18, 2020
Product Development

Mapping the path to gene therapy 2.0

...electrical light; we need a strong paradigm shift in the field of production.” Frederic Revah, Genethon...
...any other injection with the same product,” said Frederic Revah, CEO of the French non-profit Genethon...
...when they assemble the virus to improve the yield and overhaul the process.” Frederic Revah, Genethon...
BioCentury | Dec 20, 2019

CAPN3 gene therapy for limb-girdle muscular dystrophy type 2A

...published online Nov. 27, 2019 doi:10.1126/scitranslmed.aat6072 CONTACT: Isabelle Richard, Genethon, Evry, France email: richard@genethon.fr Claire Quang Genethon Calpain...
BioCentury | May 24, 2019
Finance

How Europe’s hotspots of innovation could fuel its rise as a global player in new modalities

...suites, with several trans-Atlantic companies involved. And in France, the non-profit gene therapy R&D organization Genethon...
...CRISPR Therapeutics AG, (NASDAQ:CRSP), Zug, Switzerland Fondazione Telethon, Milan, Italy Freeline Therapeutics Ltd., Stevenage, U.K. Genethon...
BioCentury | Nov 6, 2018
Distillery Techniques

Drug delivery

...Mingozzi, Institut National de la Santé et de la Recherche Médicale (INSERM), Evry, France email: fmingozzi@genethon.fr Claire...
BioCentury | Oct 5, 2018
Preclinical News

Selecta's rapamycin nanoparticles could enable re-dosing of gene therapies

...pediatric. Kishimoto said Selecta plans to submit an IND by the end of 2019. Mary Romeo SVP-Rapamycin (SEL-110) Genethon Selecta...
BioCentury | Jun 22, 2018
Clinical News

Sarepta's DMD candidate leads to microdystrophin expression of 76.2% in Phase I/IIa

...complement activation. Sarepta also has an option to another microdystrophin gene therapy from non-profit organization Genethon...
...France). That preclinical program delivers microdystrophin via an AAV2 vector (see “Sarepta Gets Option for Genethon’s...
BioCentury | Jun 19, 2018
Clinical News

Sarepta hits high on Phase I/IIa DMD readout

...Therapy” ). Sarepta also has an option to another microdystrophin gene therapy from non-profit organization Genethon...
...via an AAV2 vector (see “Sarepta Gets Option for Genethon’s DMD Gene Therapy” ). Jaime De Leon SGT-001 Genethon Sarepta...
BioCentury | Jan 12, 2018
Company News

Spark unveils gene therapy program for Pompe's

...therapy, SPK-GAA, will use a novel acid alpha glucosidase (GAA) transgene in-licensed last year from Genethon...
BioCentury | Jan 9, 2018
Company News

Spark to develop gene therapy for Pompe's

...therapy, SPK-GAA, will use a novel acid alpha glucosidase (GAA) transgene in-licensed last year from Genethon...
...fell $0.95 to $13.96 on Monday and regained $0.25 to $14.21 on Tuesday. Allison Johnson ATB200 Myozyme neoGAA Amicus Therapeutics Inc. Genethon Sanofi Spark...
Items per page:
1 - 10 of 50
BioCentury | Jun 2, 2020
Tools & Techniques

Spark’s approach to the problem of redosing AAV gene therapies

...Path to Gene Therapy 2.0” ). In Nature Medicine Monday, scientists from Spark Therapeutics Inc., Genethon...
...vaccination efficiency, pretreating with IdeS may be able to boost efficacy. Sandi Wong, Assistant Editor Spark Therapeutics Inc. Roche Genethon Institut...
BioCentury | Jan 18, 2020
Product Development

Mapping the path to gene therapy 2.0

...electrical light; we need a strong paradigm shift in the field of production.” Frederic Revah, Genethon...
...any other injection with the same product,” said Frederic Revah, CEO of the French non-profit Genethon...
...when they assemble the virus to improve the yield and overhaul the process.” Frederic Revah, Genethon...
BioCentury | Dec 20, 2019

CAPN3 gene therapy for limb-girdle muscular dystrophy type 2A

...published online Nov. 27, 2019 doi:10.1126/scitranslmed.aat6072 CONTACT: Isabelle Richard, Genethon, Evry, France email: richard@genethon.fr Claire Quang Genethon Calpain...
BioCentury | May 24, 2019
Finance

How Europe’s hotspots of innovation could fuel its rise as a global player in new modalities

...suites, with several trans-Atlantic companies involved. And in France, the non-profit gene therapy R&D organization Genethon...
...CRISPR Therapeutics AG, (NASDAQ:CRSP), Zug, Switzerland Fondazione Telethon, Milan, Italy Freeline Therapeutics Ltd., Stevenage, U.K. Genethon...
BioCentury | Nov 6, 2018
Distillery Techniques

Drug delivery

...Mingozzi, Institut National de la Santé et de la Recherche Médicale (INSERM), Evry, France email: fmingozzi@genethon.fr Claire...
BioCentury | Oct 5, 2018
Preclinical News

Selecta's rapamycin nanoparticles could enable re-dosing of gene therapies

...pediatric. Kishimoto said Selecta plans to submit an IND by the end of 2019. Mary Romeo SVP-Rapamycin (SEL-110) Genethon Selecta...
BioCentury | Jun 22, 2018
Clinical News

Sarepta's DMD candidate leads to microdystrophin expression of 76.2% in Phase I/IIa

...complement activation. Sarepta also has an option to another microdystrophin gene therapy from non-profit organization Genethon...
...France). That preclinical program delivers microdystrophin via an AAV2 vector (see “Sarepta Gets Option for Genethon’s...
BioCentury | Jun 19, 2018
Clinical News

Sarepta hits high on Phase I/IIa DMD readout

...Therapy” ). Sarepta also has an option to another microdystrophin gene therapy from non-profit organization Genethon...
...via an AAV2 vector (see “Sarepta Gets Option for Genethon’s DMD Gene Therapy” ). Jaime De Leon SGT-001 Genethon Sarepta...
BioCentury | Jan 12, 2018
Company News

Spark unveils gene therapy program for Pompe's

...therapy, SPK-GAA, will use a novel acid alpha glucosidase (GAA) transgene in-licensed last year from Genethon...
BioCentury | Jan 9, 2018
Company News

Spark to develop gene therapy for Pompe's

...therapy, SPK-GAA, will use a novel acid alpha glucosidase (GAA) transgene in-licensed last year from Genethon...
...fell $0.95 to $13.96 on Monday and regained $0.25 to $14.21 on Tuesday. Allison Johnson ATB200 Myozyme neoGAA Amicus Therapeutics Inc. Genethon Sanofi Spark...
Items per page:
1 - 10 of 50